Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI tolerability of diroximel fumarate vs dimethyl fumarate in RRMS
IRCT20260202068737N1Phase 4Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of diroximel fumarate and dimethyl fumarate in multiple sclerosis (MS) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Gastrointestinal tolerability of diroximel fumarate vs dimethyl fumarate. Started Mar 2026; status: completed.
02
Drugs
diroximel fumaratedimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20260202068737N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260202068737N1.